

HR+/HER2- Breast Cancer:

How the Latest Data Help Inform Treatment Decisions

Wednesday, May 4, 2022

18:30 – 19:30 CEST

Hamburg Hall, hub27, Berlin, Germany



Marc Thill

Chief Doctor
Clinic for Gynecology and
Gynecological Oncology
Agaplesion Markus Hospital
Germany



David Cameron

Professor of Oncology at
The University of Edinburgh
Scotland



Katarzyna Jerzak

Medical Oncologist and
Clinician Investigator
Sunnybrook Odette
Cancer Center
Canada

AGENDA

Welcome and introduction

Reaching new frontiers in the treatment of patients with HR+/HER2- advanced breast cancer

Thinking beyond HR and HER2 status in HR+/HER2- breast cancer

Striving for better outcomes in the adjuvant treatment of HR+/HER2- breast cancer

Live Q&A session

**A panel discussion will take place in between each talk*